Correction of “Notice to attend the Annual General Meeting of 2cureX AB” issued on 23[rd] April 2021.

April 24 | 2021
Corrections have been made to “Proposal for decision in brief” to item 10 “The Board of Directors' proposal for an incentive program for CEO Fernando Andreu through the issue of warrants” to clarify the calculation of the subscription price for the warrants.

The correct version is attached to this press release.

Malmö in April 2021

2cureX AB


For more information about 2cureX:

Fernando Andreu, CEO


Tel: +45 2279  5399

Certified Adviser

Redeye AB

Phone: +46 8 121 576 90


About 2cureX

2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D microtumors that functionally resemble the patient's tumor and identifies the approved cancer treatment that most effectively kills the patient's tumor. Immediately after the test, the patient is given the selected treatment.

The first IndiTreat® product in metastatic colorectal cancer is introduced to the European market. Subsequent products help patients at different stages of colorectal cancer and other solid cancers.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit